Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 August 2023 | Story Naledi Mokhasinyane | Photo Thandiswa Sihlezana
Tlotlisang Mhlambiso
Tlotlisang Mhlambiso with his new book, A Journey Worth the Ride.

Tlotlisang Mhlambiso, a University of the Free State (UFS) BEd student in his final year, wears multiple hats as an author, poet, and Teaching Assistant. And the 23-year-old’s literary prowess continues to grow: He launched his second book, a collection of short stories titled A Journey Worth the Ride, at the UFS Academy for Multilingualism recently. 

Hailing from Lugcadweni village in the Eastern Cape's Mount Fletcher (Tlokoeng), Mhlambiso self-published his debut poetry book, Ukuphuma Kwelanga, in 2020. His debut book received a public launch on 14 June 2023 at the UFS’s Sasol Library, and his second book was launched on 11 August.

Unveiling "A Journey Worth the Ride": iCAN Project hosts the remarkable launch

The launch of A Journey Worth the Ride was hosted by the iCAN Project, led by Mhlambiso's former lecturer Dr Peet van Aardt. Mhlambiso’s book delve into resilience, sorrow, and love. He was recognised by the National Youth Development Agency as 2023's Education Trailblazer. He says he hopes to battle illiteracy through his poetry and stories, which shone at the National Arts Festival and are preserved in the Amazwi South African Museum of Literature. He has also co-authored an international journal spanning continents.

Inspired by an English teacher's introduction to the poem ‘Africa My Africa’ by David Diop, Mhlambiso started writing in primary school. “We are created differently; some are vocal, and some are not,” he says. “Being part of some that are not has made me opt for writing instead of constantly being vocal about issues and situations that some people go through.” University life sparked his passion for short stories, commencing with his submission of ‘Uthando Lukamama’ to the iCAN Project. 

Empowering through words: Mhlambiso's multifaceted literary mission

Mhlambiso explains he also uses writing to address unspoken societal issues, improve literacy levels, and preserve African languages. He captures contemporary stories, aligning with the iCAN Project's aim of decolonising curricula. He envisions fostering a more literate society through reading. “Dr Peet Van Aardt once said the project is a response from the centre for the ever-increasing need for decolonised curricula, steeped in the local cultural perspective of ubuntu, which is the iCAN Project, and A Journey Worth the Ride has exactly tapped into that, as it is a multilingual book,” he added.

He believes balancing academics and writing involves limited socialising and intensive reading. Creative writing masterclasses and workshops by the Academy for Multilingualism under the iCAN Project, and the UFS African Languages Press nourish his creativity. 

From dreams to community transformation: Mhlambiso's literary odyssey

Mhlambiso hails from an environment without libraries, and now he aims to transform his community through writing. His goal is to donate his works to schools, libraries, and book clubs, promoting literacy in native languages. His poetry and stories encourage collective change and emphasise youth action. 

His works relate strongly to the UFS’s Vision 130 and one of its component values, Innovation and Impact. His aims align with this vision through his engagements with local schools, libraries, and book clubs to confront their challenges. This includes addressing issues like the scarcity of books in native languages and contributing authored works to bridge this gap. 

As Mhlambiso's oft-repeated resounding call goes: "Let's embark on this journey; it is worth the ride!” 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept